The Impact of Estrogen Replacement Therapy and Raloxifene on Osteoporosis,Cardiovascular Disease,and Gynecologic Cancers

Abstract

Spanish

French

OBJECTIVE:

To compare the clinical utility of estrogen replacement therapy (ERT) and raloxifene in osteoporosis and cardiovascular disease in postmenopausal women and to evaluate the contrasting adverse effects of these therapies.

DATA SOURCES:

A MEDLINE search was performed for January 1980 through September 1998 using the key terms raloxifene, estrogen, CVD, lipoproteins, and osteoporosis.

STUDY SELECTION AND DATA EXTRACTION:

All clinical studies assessing ERT and raloxifene in cardiovascular disease or osteoporosis were evaluated.

DATA SYNTHESIS:

ERT remains the standard for prevention and treatment of osteoporosis in women. Its use increases total bone mineral density (BMD) up to 12.1% and reduces hip fracture risk by 66–73%. It reduces low-density lipoprotein (LDL) cholesterol by 15–19% and increases high-density lipoprotein (HDL) cholesterol by 6–18%. Raloxifene, an alternative to ERT in the prevention of osteoporosis, increases total BMD by 2.2%. It reduces LDL by 6.2–14.1% and increases HDL by 1.5–5.7%. Preliminary data suggest that raloxifene has contrasting effects on gynecologic cancers compared with the increased risk posed by ERT.

CONCLUSIONS:

Clinical trials have illustrated greater effects on BMD with ERT than with raloxifene. Studies of significant duration assessing raloxifene and its fracture risk effects are lacking. ERT appears to have greater beneficial cardiovascular risk factor effects than raloxifene. Prospective, primary prevention studies evaluating overall cardiovascular risk reduction do not exist for either intervention. Raloxifene, while more costly, is an alternative that may have a lower associated risk of breast cancer compared with ERT.

Keywords

estrogen replacement therapy raloxifene postmenopause

Get full access to this article

View all access options for this article.

References

Hormone replacement therapy technical bulletin. Washington, DC: The American College of Obstetrics and Gynecology, No. 166, April 1992.

Morbidity & mortality: 1996 chartbook on cardiovascular, lung, and blood diseases. Washington, DC: National Institutes of Health-National Heart, Lung, and Blood Institute, 1996.

Mosca

Manson

Sutherland

Langer

Manolio

Barrett-Connor

. Cardiovascular disease in women. A statement for healthcare professionals from the American Heart Association. Circulation 1997: 96: 2468–82.

Consensus development conference: Diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med 1993;94: 646–50.

Kanis

Melton

III Christiansen

Johnston

Khaltaev

. The diagnosis of osteoporosis. J Bone Mner Res 1994;9: 1137–41.

Barrett-Conner

. The economic and human costs of osteoporotic fracture. Am J Med 1995;98 (suppl 2A):3S–8S.

Cummings

Rubin

Black

. The future of hip fractures in the United States: Numbers, costs, and potential effects of postmenopausal estrogen. Clin Orthop 1990;252: 163–6.

Ray

Griffin

Baugh

. Mortality following hip fracture before and after implementation of the prospective payment system. Arch Intern Med 1990;150: 2109–14.

Lobo

. Effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991;73: 925–30.

10.

Eriksen

Colvard

Berg

Graham

Mann

Spelsberg

. Evidence of estrogen receptors in normal human osteoblast-like cells. Science 1988;241: 84–8.

11.

Karas

Patterson

Mendelsohn

. Human vascular smooth muscle cells contain functional estrogen receptor. Circulation 1994;89: 1943–50.

12.

Losordo

Kearney

Kim

Jekanowski

Isner

. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. Circulation 1994;89: 1501–10.

13.

Folsom

Mnk

Sellers

Hong

Zheng

Potter

. Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health 1995;85: 1128–32.

14.

Stampfer

Willett

Colditz

Rosner

Speizer

Hennekens

. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313: 1044–9.

15.

Stampfer

Colditz

Willett

Manson

Rosner

Speizer

Postmenopausal estrogen therapy and cardiovascular disease — Ten-year follow-up from the Nurses' Health Study. N Engl J Med 1991;325:756–62.

16.

Grodstein

Stampfer

. The epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis 1995;38: 199–210.

17.

Stampfer

Colditz

. Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence. Prev Med 1991;20: 47–63.

18.

Sullivan

Zwaag

Hughes

Maddock

Kroetz

Ramanathan

Estrogen replacement and coronary artery disease — Effect on survival in postmenopausal women. Arch Intern Med 1990: 150:2557–62.

19.

Sullivan

Zwaag

Lemp

Hughes

Maddock

Kroetz

Postmenopausal estrogen use and coronary atherosclerosis. Ann Intern Med 1988;108:358–63.

20.

The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/ progestin regimens on heart disease risk factors in postmenopausal women. JAMA 1995;273: 199–208.

21.

Koh

Cardillo

Bui

Hathaway

Csako

Waclawiu

Vascular effects of estrogen and cholesterol-lowering therapy in hypercholesterolemic postmenopausal women. Circulation 1999;99:354–60.

22.

Gruchow

Anderson

Barboriak

Sobocinski

. Postmenopausal use of estrogen and occlusion of coronary arteries. Am Heart J 1988;115: 954–63.

23.

Rajkumar

Kingwell

Cameron

Waddell

Mehra

Christophidis

Hormonal therapy increases arterial compliance in postmenopausal women. J Am Coll Cardiol 1997;30:350–6.

24.

Lieberman

Gerhard

Uehata

Walsh

Selwyn

Ganz

Estrogen improves endothelium-dependent, flow-mediated vasodilation in postmenopausal women. Ann Intern Med 1994;121:936–41.

25.

Haines

Chung

Chang

Masarei

Tomlinson

Wong

. Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. Arch Intern Med 1996;156: 866–72.

26.

Sacks

McPherson

Walsh

. Effect of postmenopausal estrogen replacement on plasma Lp(a) lipoprotein concentrations. Arch Intern Med 1994;154: 1106–10.

27.

Soma

Osnago-Gadda

Paoletti

Fumagalli

Morrisett

Meschia

The lowering of lipoprotein (a) induced by estrogen plus progesterone replacement therapy in postmenopausal women. Arch Intern Med 1993;153:1462–8.

28.

The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. JAMA 1996;275: 370–5.

29.

Colditz

Hankinson

Hunter

Willett

Manson

Stampfer

The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med 1995;332:1589–93.

30.

The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on bone mineral density. JAMA 1996;276: 1389–96.

31.

Speroff

Rowan

Symons

Genant

Wilborn

. The comparative effect on bone density, endometrium, and lipids of Continuous Hormones as Replacement Therapy (CHART Study). JAMA 1996;276: 1397–403.

32.

Mzunuma

Okano

Soda

Kagami

Myamoto

Tokizawa

Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: A 2 year prospective study. Maturitas 1997;27:69–76.

33.

Felson

Zhang

Hannan

Kiel

Wilson

PWF

Anderson

. The effect of postmenopausal estrogen therapy on bone density in elderly women. N Engl J Med 1993;329: 1141–6.

34.

Eiken

Nielsen

S Pors

Kolthoff

. Effects on bone mass after 8 years of hormone replacement therapy. Br J Obstet Gynaecol 1997;104: 702–7.

35.

Schneider

Barrett-Connor

Morton

. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study. JAMA 1997;277: 543–7.

36.

Kiel

Felson

Anderson

Wilson

PWF

Moskowitz

. Hip fracture and the use of estrogens in postmenopausal women. N Engl J Med 1987;317: 1169–74.

37.

Cauley

Seeley

Ensrud

Ettinger

Black

Cummings

. Estrogen replacement therapy and fractures in older women. Ann Intern Med 1995;122: 9–16.

38.

Lufkin

Wahner

O'Fallon

Hodgson

Kotowicz

Lane

Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 1992;117:1–9.

39.

Draper

Flowers

Huster

Neild

Harper

Arnaud

. A controlled trial of raloxifene (LY139481) HC1: Impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Mner Res 1996;11: 835–42.

40.

Delmas

Bjarnason

Mitlak

Ravoux

Shah

Huster

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–7.

41.

Kim

Ryu

Kwak

Park

Ryoo

. Changes in Lp(a) lipoprotein and lipid levels after cessation of female sex hormone production and estrogen replacement therapy. Arch Intern Med 1996;156: 500–4.

42.

Walsh

Schiff

Rosner

Greenberg

Ravnikar

Sacks

. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325: 1196–204.

43.

Hulley

Grady

Bush

Furberg

Herrington

Riggs

Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605–13.

44.

Walsh

Kuller

Wild

Paul

Farmer

Lawrence

. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998;279: 1445–51.

45.

Pike

Peters

Cozen

Probst-Hensch

Felix

Wan

Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 1997;89:1110–6.

46.

Woodruff

Pickar

. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol 1994;170: 1213–23.

47.

Stanford

Weiss

Voigt

Daling

Habel

Rossing

. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274: 137–42.

48.

Dupont

Page

. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151: 67–72.

49.

Steinberg

Thacker

Smith

Stroup

Zack

Flanders

A meta-analysis of the effect of estrogen replacement on the risk of breast cancer. JAMA 1991;265:1985–90.

50.

Sellers

Mnk

Cerhan

Zheng

Anderson

Kushi

The role of hormone replacement therapy in the risk for breast cancer and total mortality in women with a family history of breast cancer. Ann Intern Med 1997;127:973–80.

51.

Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormone replacement therapy: Collaborative reanalysis of data from 51 epidemiologic studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Lancet 1997;350: 1047–59.

52.

Boss

Huster

Neild

Giant

Eisenhunt

Draper

. Effects of raloxifene hydrochloride on the endometrium of postmenopausal women. Am J Obstet Gynecol 1997;177: 1458–64.

53.

Cummings

Eckert

Krueger

Grady

Powles

Cauley

The effect of raloxifene on risk of breast cancer in postmenopausal women — Results from the MORE randomized trial. JAMA 1999;281:2189–7.

54.

Turner

Sato

Bryant

. Raloxifene preserves bone strength and bone mass in ovariectomized rats. Endocrinology 1994;135: 2001–5.

55.

Package insert. Evista (raloxifene hydrochloride). Indianapolis: Eli Lilly and Company, 1997.

56.

Mitlak

Cohen

. In search of optimal long-term female hormone replacement: The potential of selective estrogen receptor modulators. Horm Res 1997;48: 155–63.

57.

McDonnell

Clemm

Hermann

Goldman

Pike

. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens. Mol Endocrinol 1995;9: 659–69.

58.

Black

Sato

Rowley

Magee

Bekele

Williams

Raloxifene (LY139481) HC1 prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats. J Clin Invest 1994;93:63–9.

59.

Wakeling

Valacaccia

Newboult

Green

. nonsteroidal antioestrogens — Receptor binding and biological response in rat uterus, rat mammary carcinoma and human breast cancer cells. J Steroid Biochem 1984;20: 111–20.

60.

Gelfand

Ferenczy

. A prospective 1-year study of estrogen and progestin in postmenopausal women: Effects on the endometrium. Obstet Gynecol 1989;74: 398–402.

61.

Gambrell

Jr . Clinical use of progestins in the menopausal patient: Dosage and duration. J Reprod Med 1982;27 (suppl 8): 531–8.

62.

Magos

Brincat

Studd

JWW

Wardle

Schlesinger

O'Dowd

. Amenorrhea and endometrial atrophy with continuous oral estrogen and progestogen therapy in postmenopausal women. Obstet Gynecol 1985;65: 496–9.

63.

Ryan

Harrison

Blake

Fogelman

. Compliance with hormone replacement therapy (HRT) after screening for postmenopausal osteoporosis. Br J Obstet Gynaecol 1992;99: 325–8.

64.

Doren

Reuther

Minne

Schneider

HPG

. Superior compliance and efficacy of continuous combined oral estrogen-progestogen replacement therapy in postmenopausal women. Am J Obstet Gynecol 1995;173: 1446–51.

65.

Cardinale

, ed. 1998 Drug topics red book. Montvale, NJ: Medical Economics Co., 1998.

66.

Ettinger

Black

Mitlak

Knickerbocker

Nickelsen

Genant

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 1999;282: 637–45.